GE Healthcare aims to end unpredictability in early drug research
This article was originally published in Scrip
Better consistency of the cells used in early-stage drug research could save R&D departments millions of dollars and a lot of wasted time and effort. At GE Healthcare, the commercialisation of reliable stem cell lines is just around the corner, head of cell technologies R&D Dr Stephen Minger tells Ashley Yeo.
You may also be interested in...
How UK and EU device regulations will differ in 2021, UK approved bodies and Northern Ireland's unfettered access to the UK market were key themes at the ABHI’s annual regulatory conference.
2019 saw fewer revenue-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.
If the tools are not in place by the end of 2020 to allow diagnostics companies to comply with the EU IVDR, the 2022 compliance deadline should be delayed, say EU notified bodies.